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This study evaluates the potential use of zein as an excipient in hot-melt extrusion for 31 
controlled delivery of diclofenac sodium (DS). Mixtures of zein, polyethylene glycol and 32 
drug were hot melt extruded and cut into 2 mm extrudates. Extrudates were characterised 33 
using differential scanning calorimetry, X-ray powder diffraction and scanning electron 34 
microscopy. The drug in the extrudates was found to be in the non-crystalline state, 35 
independent of the drug loading. Moreover, the drug release from extrudates was 36 
investigated. The release was directly dependent on the drug loading: a controlled and nearly 37 
zero-order release was obtained at the lowest drug loading (12.5% w/w), whereas almost 38 
immediate release was achieved at higher drug loadings, i.e. 25% and 37.5%. The release was 39 
inversely dependent on the ionic strength of the medium. The influence of digestive enzymes 40 
on drug release was also studied. Pancreatin, but not pepsin, was found to have a significant 41 
influence on the drug release as well as on the microstructure of zein extrudates. These data 42 
therefore support the potential use of zein as excipient in hot melt extrusion for controlled 43 
release purposes. 44 
 45 
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1. Introduction  56 
 57 
Controlled-release oral dosage forms are designed to achieve drug release characteristics over 58 
a specific time course that can offer certain therapeutic objectives over conventional dosage 59 
forms. Polymeric excipients have been used in oral formulations to control drug release rate. 60 
Although synthetic and semisynthetic polymers have been extensively used for this purpose, 61 
natural excipients, being both sustainable and biodegradable, are being increasingly used. 62 
Zein, for example, is a plant-derived protein, that has been extensively studied for its 63 
potential use as an excipient in the pharmaceutical industry (Berardi et al., 2018).  64 
 65 
Zein is the major storage protein of corn (Shukla and Cheryan, 2001), and constitutes 44-79% 66 
of the endospermic proteins (Lawton, 2002). It is composed of  a mixture of different 67 
peptides that can be classified on the basis of their solubility and molecular weight into α (19 68 
and 22 kDa), β (17-18 kDa), γ (16 and 27 kDa) and δ (10 kDa) zeins (Esen, 1986). Zein is 69 
particularly rich in hydrophobic amino acids, but deficient in polar or ionisable amino acids 70 
(Cabra et al., 2006; Shukla and Cheryan, 2001). Zein is a natural, biocompatible and 71 
biodegradable material produced from sustainable sources (Berardi et al., 2018). Due to its 72 
amino acid composition, zein is insoluble in water, yet is soluble in aqueous ethanol 73 
solutions. Despite its insolubility in water, zein tends to swell in the presence of aqueous 74 
medium (Beck et al., 1996). This is because zein has hydrophilic regions in addition to the 75 
hydrophobic domains, and thus behaves as an amphiphilic protein (Wang et al., 2008). 76 
Indeed, zein matrices were found to swell in a hydrophilic-like fashion, but were non-77 
erodible as hydrophobic matrices (Berardi et al., 2017b). Being swellable, yet insoluble and 78 
nonerodable, zein has been also studied for its potential use as an excipient for controlled 79 
drug release in nano- and microscale as well as macroscale formats. Zein tablets (Berardi et 80 
al., 2017a; Georget et al., 2008; Katayama and Kanke, 1992; Li et al., 2010; O’Donnell et al., 81 
1997; Raza et al., 2020, 2019) and capsules (Berardi et al., 2017b) were successfully 82 
developed for controlled release purposes. However, the potential use of zein biopolymer as 83 
an excipient for direct compression could be limited by its poor flowability and tabletability, 84 
compared to the commonly used excipients, as suggested by Berardi et al. (Berardi et al., 85 
2017a). Similarly, Georget et al. (Georget et al., 2008) reported that tablets core were striated 86 
in appearance, due to the elastic recovery of zein upon removal of the compression force.  87 
 88 
Hot melt extrusion (HME) technique involves forcing raw materials using a rotating screw(s) 89 
through a die of a defined geometry under elevated temperature (Crowley et al., 2007).  HME 90 
is a continuous and solvent free process, reducing the number of steps and eliminating the 91 
drying step (Crowley et al., 2007). Recently, Zein has proved to be a promising new excipient 92 
for HME for the development of controlled drug delivery systems (Bouman et al., 2016, 93 
2015). Despite being a protein, it has been shown that zein is relatively heat stable and can be 94 
extruded at high temperatures (up to 160 °C) without significant changes in its molecular or 95 
physical properties (Selling, 2010). Zein and paracetamol physical mixtures were hot-melt 96 
extruded injection moulded into single-matrix phase, homogenous caplets by Bouman et al. 97 
(Bouman et al., 2015). Controlled drug release was obtained and was found to be strongly 98 
dependent on device dimensions but nearly independent of drug loading. In another work, 99 
Bouman et al. studied the influence of drug hydrophobicity as well as the influence of 100 
electrostatic interactions between drug and polymer, which is governed by pH medium, on 101 
drug release (Bouman et al., 2016). They found out that the release kinetics were not mainly 102 
determined by water solubility of the drug, yet the electrostatic attractions between zein 103 
matrix and drug can significantly slow down the release.  104 
 105 
In this work, we developed controlled release zein matrices of diclofenac sodium (DS) using 106 
hot melt extrusion. DS is a BCS class II drug that is insoluble at acidic pH, yet soluble at 107 
more basic intestinal pH (Chuasuwan et al., 2009), justifying its widespread use in controlled 108 
release dosage forms (Jantratid et al., 2009; Rani and Mishra, 2004). The physical state of the 109 
model drug was characterised by differential scanning calorimetry (DSC) and X-ray powder 110 
diffraction (XRPD). Dissolution studies were performed to investigate the effect of drug 111 
loading and composition of dissolution medium on drug release. The influence of the medium 112 
ionic strength on drug release from zein extrudates was evaluated here for the first time. We 113 
also studied the influence of pH switch, i.e. pH 1.2 to pH 7.5, and that of the presence of 114 
digestive enzymes on the drug release and on the microstructure of zein extrudates. The 115 
objective of this article is therefore to gain an understanding of what are the key factors that 116 
might influence the performance of zein extrudates in conditions simulating the 117 
heterogeneous environment of the upper gastrointestinal tract, and could ultimately dictate 118 
zein’s applications. 119 
 120 
2. Materials and Methods 121 
2.1 Materials 122 
 123 
Zein from maize (Z3625) was obtained from Sigma-Aldrich (Germany) and used as received. 124 
This product was plasticized with polyethylene glycol 400, PEG 400, obtained from Merck-125 
Schuchardt (Germany). The model drug, diclofenac sodium was obtained from Aarti drugs 126 
Ltd. (India) and was used as received. Diclofenac sodium was chosen on the basis that an 127 
extended release formulation of this, some are already available in market, can prove useful 128 
in management of signs and symptoms of patients with osteoarthritis and rheumatoid 129 
arthritis. Pepsin (p7125) and pancreatin (p8096) enzymes were purchased from Sigma-130 
Aldrich (USA). Other materials used for the preparation of the dissolution media were 131 
reagents of standard grades and were supplied by AZ chem and Alpha Chemika (India). 132 
 133 
2.2 Methods 134 
 135 
2.2.1 Hot melt extrusion  136 
Zein powder was first granulated in a wet granulation step in order to improve its flow 137 
properties. PEG 400, added as an aqueous solution during granulation, was used to lower the 138 
glass transition temperature (Tg) of zein. Zein and PEG 400 (10 or 20% of the total weight) 139 
were mixed using a mortar and pestle until a suitable granule was formed. At concentrations 140 
greater than 20% PEG, the granulation process was not possible. The wet granulation was 141 
sieved through a 1 mm sieve, and then dried in oven at 50 °C overnight. The dried granules 142 
were sieved again through the same sieve before being stored in a plastic bottle. The residual 143 
moisture content was measured by the "loss on drying" (LOD) in triplicate using a moisture 144 
balance (Mettler PE 160, USA). The LOD of granules containing 10% and 20% PEG 400 145 
was 3.75% (± 0.78) and 3.98% (± 0.32), respectively.  146 
 147 
Blends of pre-plasticized zein granules and different amounts of diclofenac sodium were 148 
prepared to obtain formulations with drug loading ranging from 12.5% to 37.5% (w/w). The 149 
mixtures were hot-melt extruded using a single-screw extruder (Randcastle microtruder, 150 
USA) (Andrews et al., 2008; Young et al., 2002), fitted with a cylindrical die with an inner 151 
diameter of 5 mm. The extrusions were performed at a temperature of 140 °C for all zones, 152 
i.e. zone 1, 2 ,3 and 4, and a screw speed of 20 rpm. Extrudates were allowed to cool down 153 
and then stored in sealed containers at room conditions.  154 
 155 
The composition of zein extrudates is reported in Table 1. A special notation (e.g., 156 
E_12.5_20) was used to describe the preparation conditions: the letter E stands for extrudate, 157 
the first number is the concentration of diclofenac sodium (w/w%) and the second number is 158 
the plasticizer level (w/w%) with respect to the total weight of zein and PEG 400. 159 
 160 
2.2.2 Drug Content 161 
Extrudates were ground using mortar and pestle. An amount equivalent to 25 mg of 162 
diclofenac sodium was weighed and transferred to a 100 ml volumetric flask and phosphate 163 
buffer pH 7.5 was added. The flask was stirred for 1 hour using a magnetic bar and was then 164 
sonicated in a bath sonicator for another 1 hour with intermittent shaking. The volume was 165 
made to 100 mL and a 10 mL sample was taken and filtered using 0.45µm PTFE filters. The 166 
samples were analysed for diclofenac sodium by high-performance liquid chromatography 167 
(HPLC; Knauer, Leeds, UK). The mobile phase consisted of water- methanol (30:70 v/v) 168 
adjusted to pH 3.5 with glacial acetic acid and pumped at 1 mL.min-1 through a C18, 5 µm, 169 
250 x 4.6 mm column (Thermo Scientific, USA). UV detection was carried out at 276 nm. 170 
The measurements were performed in triplicate and the averages and standard deviations 171 
were calculated. The drug content of zein extrudates is reported in Table 1. 172 
 173 
2.2.3 Differential Scanning Calorimetry (DSC) 174 
DSC analysis of diclofenac sodium (DS) raw powder, zein raw powder, physical mixtures of 175 
DS and zein powder or granulated zein as well as DS loaded zein extrudates was carried out 176 
using DSC 250 (TA Instruments, USA). Approximately 5 mg samples were sealed in 177 
standard aluminium DSC pans. Extrudates were crushed using mortar and pestle before 178 
measurements. The samples were heated from 25°C to 350°C at a heating rate of 10°C/min, 179 
under nitrogen purge (50 ml/min). 180 
 181 
2.2.4 X-Ray Powder Diffraction (XRPD) 182 
X-Ray Powder Diffraction analysis of diclofenac sodium (DS) raw powder, zein raw powder, 183 
physical mixtures of DS and zein powder or granulated zein as well as DS loaded zein 184 
extrudates was carried out using XRD-7000 X-Ray Diffractometer (Shimadzu, Japan). The 185 
diffraction pattern was recorded using monochromatic Cu radiation (λ= 1.54 A°) as anode 186 
material and operated at a voltage of 40 kV and a current of 30 mA. The samples were 187 
mounted on Al sample holder and XRD patterns were recorded in the range of 2–60° at the 188 
speed of 2°/min and a sampling pitch of 0.02°. 189 
 190 
2.2.5 Dissolution Studies 191 
Dissolution studies were carried out at 37 ± 0.5 °C in a BP dissolution apparatus I (ERWEKA 192 
DT 600, ERWEKA GmbH, Germany), with a rotation speed of 100 rpm. Extrudates were 193 
manually cut into pieces of 2 mm long using a cutting blade. An appropriate amount of the 194 
previously cut extrudates (2 mm) of each formulation (Table 1), equivalent to 25 mg drug, 195 
was weighed and placed in the basket. The tests were performed in 50 mM phosphate buffer 196 
(pH 7.5), as recommended by USP monograph for diclofenac sodium extended release 197 
tablets, or otherwise in 900 mL of water; 100 mM phosphate buffer (pH 7.5); 200 mM 198 
phosphate buffer (pH 7.5); 50 mM phosphate buffer (pH 7.5) + 0.1 M NaCl; 50 mM 199 
phosphate buffer (pH 7.5) + 0.2 M NaCl. Ten mL samples were withdrawn at predetermined 200 
times using a syringe, filtered through a 0.45 μm PTFE membrane filter (Macherey-Nagel 201 
GmbH & Co. KG, Germany) and replaced with an equivalent volume of fresh medium. The 202 
diclofenac sodium concentration was determined using a UV-VIS spectrophotometer 203 
(SpectroScan 80D, Cyprus) set at as wavelength of 276 nm and with reference to an 204 
appropriate standard curve. The dissolution studies were carried out in triplicate and the 205 
average drug release (calculated based on actual drug content) ± SD was calculated.  206 
 207 
Dissolution studies under conditions that more closely resemble those in the upper 208 
gastrointestinal tract were also carried out. In this case, freshly prepared simulated gastric 209 
fluid (SGF) (2 g L-1 NaCl and 3.2 g L-1 pepsin) pH 1.2 was used as the dissolution medium 210 
for the first 2 hours. This medium was then replaced by freshly prepared simulated intestinal 211 
fluid (SIF) (6.8 g L−1 KH2HPO4, 10 g L
-1 pancreatin) pH 7.5 for an additional 22 hours. 212 
Control experiments using SGF without pepsin for 2 hours followed by 22 hours in SIF 213 
without pancreatin were run in parallel. Diclofenac is a weak acid (pKa=4) and thus 214 
practically insoluble in acid. In order to measure the amount of the drug released in acidic 215 
media, the media were neutralized at the end of the 2-hour test in SGF with or without pepsin 216 
by adding 20 mL of 5M NaOH and stirring using paddles for 5 minutes. Then a sample was 217 
withdrawn and filtered through 0.45 µm filters prior to analysis for diclofenac sodium by 218 
high-performance liquid chromatography (HPLC; Knauer, Leeds, UK). In SIF with 219 
pancreatin, ten-mL samples were removed at predetermined times over a 22-hour period, 220 
centrifuged at 13,000 rpm for 30 minutes, and filtered through 0.45 µm filters prior to 221 
analysis for diclofenac sodium by high-performance liquid chromatography (HPLC; Knauer, 222 
Leeds, UK), using the same method described in Section 2.2.2. 223 
 224 
2.2.6 Scanning Electron Microscopy (SEM) 225 
The surface morphology of zein extrudates prior and after testing in media was studied using 226 
SEM. Samples were mounted onto stubs using double-sided tape and were platinum coated 227 
by a Emitech K550 X sputter coater manufactured by Quorum Technologies (England). The 228 
imaging process was performed in a high vacuum environment. Imaging process was 229 
performed with a FEI Inspect F50 SEM (Netherlands), mounted with a tungsten filament with 230 
an acceleration voltage of 1-30 kV. 231 
 232 
3. Results 233 
 234 
3.1 Characterization of Drug-Loaded Zein Extrudates 235 
 236 
DSC and XRPD studies were engaged for determination of the physical state of the model 237 
drug, diclofenac sodium, in the prepared zein extrudates. Physical mixtures of DS and zein or 238 
granulated zein as well as DS and zein raw powders were used as controls.  239 
 240 
DSC thermograms of DS and zein raw powders, physical mixtures of DS and zein powder or 241 
granulated zein and zein extrudates of two different drug loadings are demonstrated in Figure 242 
1. Zein powder showed a very broad endotherm with onset at 50 °C and peak temperature 243 
around 90 °C. This can be associated with water loss (Tillekeratne and Easteal, 2000). The 244 
glass transition temperature of zein was observed at 168.4 °C which is in agreement with 245 
previous reports (Doğan Atik et al., 2008; Tillekeratne and Easteal, 2000). After 255 °C, the 246 
degradation of zein started with an exothermic peak coupled with an endothermic peak at 300 247 
°C that has been attributed to thermal denaturation of zein through the breakdown of 248 
hydrogen bonds, electrostatic interactions, and dipole-dipole interactions and subsequent loss 249 
of tertiary protein structure (Gaona-Sánchez et al., 2015; Tillekeratne and Easteal, 2000). 250 
Beyond 330 °C, the exothermic degradation prevailed. 251 
 252 
The glass transition temperature of zein was still evident in the physical mixture of zein and 253 
DS (PM_Zein-DS 12.5%), however, it disappeared upon the incorporation of PEG used in the 254 
granulation of zein in PM_Granulated zein-DS 12.5%. PEG acts as a plasticizer reducing the 255 
glass transition temperature of zein and making it difficult to be determined as it is shifted 256 
towards a lower temperature and is possibly overshadowed by the evaporative endotherm 257 
(Tillekeratne and Easteal, 2000). The onset of the thermal degradation peak of PM_Zein-DS 258 
12.5% started at the same temperature as that of the zein alone sample (≈ 255 °C). However, 259 
the degradation of samples containing PEG 400 was seen at a lower temperature. This is 260 
possibly due to the thermal degradation of PEG 400 which starts at around 200 °C, as shown 261 
in previous thermogravimetric analysis data (Phaechamud and Chitrattha, 2016). 262 
 263 
The DSC thermogram of DS showed two endothermal events with a sharp peak at 53.44 °C 264 
and a broad one at 80.49 °C which correspond to the dehydration of DS tetrahydrate. A sharp 265 
endothermic melting peak at 287.55 °C was observed and followed by decomposition (Bettini 266 
et al., 2004, 2000; Pasquali et al., 2007). The endothermic melting peak however disappeared 267 
in the DSC thermogram of PM_Zein-DS 12.5%. This is because the thermal degradation of 268 
zein overshadowed the melting transition of the drug. Similarly, the drug peak was absent in 269 
all other samples containing drug and zein. Therefore, the overlap of zein and drug transitions 270 
precluded the determination of the physical state of the drug using DSC.  271 
 272 
X-ray diffraction was used to analyze the degree of drug crystallinity in the studied samples. 273 
As indicated by X-ray examinations (Figure 2), DS raw powder manifested the distinct peaks 274 
of highly crystalline DS tetrahydrate, while there were no clear peaks in the X-ray 275 
diffractogram for the amorphous zein. The X-ray spectra of physical mixtures of zein and DS 276 
showed that the intensities of typical peaks for raw drug were lowered by the dilution effect 277 
of zein, particularly at low DS content (i.e. PM_Zein-DS 12.5%).  278 
 279 
PM_Granulated zein-DS 12.5%, unlike PM_Zein-DS 12.5%, did not show any discernible 280 
peaks and the diffraction pattern corresponded closely to that of amorphous zein. However, 281 
the diffraction peaks of DS were seen in PM_Granulated zein-DS 37.5% sample, albeit at 282 
lower intensity compared to those observed with PM_Zein-DS 37.5%. The reduction in the 283 
crystallinity of the granulated samples containing PEG 400 could be explained by the 284 
solubilisation of DS by PEG 400 (Khalil et al., 2000). These results suggest that the 12.5% of 285 
DS was completely solubilized by PEG 400, whereas PEG 400 was saturated with DS at 37% 286 
drug loading and the remaining fraction of insolubilized drug contributed to the peaks 287 
observed in the diffractogram of that sample.  288 
 289 
Finally, the extruded samples (E_12.5_20; E_37.5_20) were characterized by the absence of 290 
the diffraction peaks in XRPD, signifying a drug amorphousization. The fact that amorphous 291 
pattern was obtained even at the highest DS content, i.e. 37.5% indicates that the extrusion 292 




3.2 In Vitro Drug Release Studies 297 
 298 
3.2.1 Effect of Drug Loading  299 
 300 
The effect of drug loading on drug release was first evaluated. Figure 3 compares the 301 
dissolution profiles of zein extrudates of four different drug loadings: 12.5%, 18.75%, 25% 302 
and 37.5% w/w in phosphate buffer pH 7.5. The higher the drug loading the faster was the 303 
drug release. Samples with the higher drug loadings, i.e. 25% and 37.5% showed almost 304 
immediate release profiles with circa 75% and 80% of drug being released in 1 hour, 305 
respectively. The drug release was the slowest from 12.5% DS loaded extrudates and 306 
approached zero order release kinetics over the test duration, without initial burst release. The 307 
release profile from 18.75% DS loaded extrudates was biphasic with a rapid release of the 308 
drug easily accessible at the surface of the extrudates and a slower second phase where 309 
diffusion occurs. Bouman et al. (Bouman et al., 2015) have previously found that the drug 310 
release from zein hot melt extruded injection moulded caplets was dependent on drug loading 311 
in the case of ranitidine, but not in the case of paracetamol and indomethacin.  312 
 313 
Zein is a swellable, nonerodable polymer, and drug release is thus expected to occur via 314 
diffusion through pores between the polymeric chains or those created upon the dissolution of 315 
the soluble components. In other words, increasing the drug % increases the soluble 316 
component, and simultaneously decreases the insoluble zein component, in the formulation, 317 
which upon dissolution creates more pores through which the drug can be released. In 318 
addition, the higher the concentration of the hydrophilic drug salt within the formulation, the 319 
greater is the overall hydrophilicity of the whole system. Higher hydrophilicity might 320 
translate into more rapid hydration (Bouman et al., 2016) and drug release. However, the 321 
differences in drug release could not be attributed to the physical state of the drug in the 322 
extrudates, as DS was present in the non-crystalline state at the lowest and highest drug 323 
loadings, as shown by the solid-state characterization discussed earlier.  324 
 325 
3.2.2 Effect of Buffer Concentration and Ionic Strength of Medium on Drug 326 
Release 327 
 328 
In addition to the standard compendial medium, i.e. 50 mM phosphate buffer of pH 7.5, 329 
diclofenac sodium release from zein extrudates was tested in media with different ionic 330 
strengths, i.e. in phosphate buffers of different buffer concentrations and in 50 mM phosphate 331 
buffer with added amounts of NaCl. These tests have been done because zein swelling is 332 
known to be dependent on pH and ionic strength of the medium. Formulation E_12.5_20 was 333 
selected for the studies described in this section. This is because this formulation exhibited a 334 
controlled release behaviour, and it is therefore more likely to be discriminative, compared to 335 
the other formulations.  336 
 337 
Figure 4 compares the dissolution profiles of DS from the extrudates in phosphate buffers 338 
(pH 7.5) of different buffer concentrations (50, 100 and 200 mM). Water (used as a 339 
reference), 50, 100, and 200 mM PB have approximately ionic strength values of 0, 90, 180, 340 
360 mM, respectively. This range of ionic strength of the medium has been used to simulate 341 
the effect of gastro-intestinal fed and fasted states on drug release from extended release 342 
matrices (Asare-Addo et al., 2013a, 2013b). An increase in the buffer concentration from 0 to 343 
200 mM resulted in slower drug release. This result is in agreement with Berardi et al. 344 
(Berardi et al., 2017b) where drug release from zein filled into hard gelatin capsules was 345 
inversely dependent on PB concentration. The authors related the differences in drug release 346 
in phosphate buffers of different ionic strengths to hydration/ swelling of zein protein. 347 
Swelling of zein was found to be inversely proportional to the ionic strength of the medium. 348 
Thus, the greater swelling at lower ionic strengths increased the porosity of the matrix, i.e. 349 
the number and/or size of the channels, and ultimately increased the drug release. However, 350 
in this study it can be observed that the release in water became slower than that in 50 mM 351 
PB after 8 hours. This is most likely due to the lack of buffer capacity of water and the 352 
subsequent decrease in DS solubility in water as more acid drug dissolves into the medium. 353 
 354 
Human intestinal fluids contain bicarbonate buffer rather than phosphate buffer (Sheng et al., 355 
2009). Moreover, the buffering capacity in vivo has been found to be much inferior to that of 356 
50 mM phosphate buffers (Hens et al., 2017; Tsume et al., 2012). This means that drugs, 357 
especially BCS class II weak acid drugs, could exhibit faster dissolution in vitro than in vivo, 358 
due to the higher pH and buffer capacity in vitro. Indeed, it has been calculated that the buffer 359 
capacity of bicarbonate buffers in vivo is equivalent to that of 8 – 45 mM phosphate buffers 360 
(Tsume et al., 2012). Further studies have shown that even lower phosphate buffer 361 
concentrations (1– 25 mM) are usually more biorelevant in simulating the influence of 362 
bicarbonate buffers on the dissolution of weak acid drugs (Krieg et al., 2015). We can thus 363 
speculate that the slower release of diclofenac sodium in water compared to 50 mM PB might 364 
also occur, although to a lower extent, in vivo, where the buffer capacity is expected to be 365 
intermediate between the two media (i.e. water and 50 mM PB) investigated here. 366 
 367 
Next, we tested the effect of addition of NaCl into phosphate buffer on drug release. Figure 5 368 
shows the drug release of DS from the extrudates in media containing increasing 369 
concentrations of salt. It can be observed that the addition of 0.1 M NaCl (ionic strength 190 370 
mM) in the buffer slowed down the drug release. However, no further decrease in drug 371 
release was obtained as the amount of NaCl was increased to 0.2 M. The obtained results are 372 
qualitatively and quantitatively similar to those of Figure 4. Again here, the decrease in drug 373 
release at increasing ionic strengths could be attributed to reduced swelling of zein matrices 374 
(Berardi et al., 2017b).  375 
 376 
3.2.3 Effect of pH Medium and Enzymes on Drug Release 377 
 378 
Performing a dissolution test with a two hours pre-incubation in SGF (without enzymes), 379 
followed by a switch to SIF (without enzymes) for the remaining time enables to simulate the 380 
effect of the gastric acid on the performance of the drug delivery system (Berardi et al., 381 
2017a; Corti et al., 2008). This is particularly important for zein-based dosage forms which 382 
are known to swell more in acidic compared to more basic environments (Berardi et al., 383 
2017a; Bouman et al., 2016, 2015). DS (pKa = 4) is practically insoluble at pH ≈ 1 of the 384 
simulated gastric fluids (SGF) (Kincl et al., 2004). The low solubility precludes the drug 385 
diffusion from the dosage form. Indeed, the drug release in SGF was lower than in PB during 386 
the first two hours (Figure S1). Thereafter, the profiles in SIF and PB became rapidly 387 
superimposable, indicating that the pre-treatment in acid did not compromise the ability of 388 
the zein matrix to control the drug release. This is probably because, the preferential swelling 389 
of zein in acid is thought to be reversible (Berardi et al., 2018, 2017a).  390 
 391 
Next, we studied the influence of the digestive enzymes on the drug release. Understanding 392 
the effect of proteases on the delivery system is of foremost important, given that zein is a 393 
protein. For this purpose, we compared the drug dissolution in SGF, followed by SIF either in 394 
presence or in absence of digestive enzymes, i.e. pepsin and pancreatin, respectively. Results 395 
are shown in Figure 6: digestive enzymes had a significant influence on the drug release. In 396 
the first two hours in SGF the drug release was only minimally affected by the presence of 397 
pepsin. However, upon switching to SIF, the drug release was much faster in the presence 398 
rather than in the absence of pancreatin, with circa 86% and 33% of the drug being released 399 
after a 12 hour-test duration, respectively.  400 
 401 
To investigate this further, we took optical and SEM images of the extrudates before 402 
incubation (Figure 7A) and after incubation in SGF (Figure 7B), SIF (Figure 7C) and SGF 403 
followed by SIF (Figure 7D) both in presence and absence of enzymes. A comparison of the 404 
images in Figure 7A and B reveals that the extrudates remained smooth both in the dry state 405 
and upon incubation in SGF without pepsin. In the presence of pepsin, the surface appeared 406 
slightly more striated and some superficial pores showed in the structure. However, the 407 
structural changes were microscopic and just on the surface. In contrast, the presence of 408 
pancreatin in SIF resulted in major morphological changes (Figure 7C): the structure of 409 
extrudates became an open network of pores visible both at the macroscopic and microscopic 410 
levels, while it was solid in the absence of pancreatin. This indicates that pancreatin eroded 411 
the zein-matrix by digestion. Figure 7D shows that the combined effect of pepsin and 412 
pancreatin led to the formation of large and small pores in the structure. However, the erosion 413 
was less than that observed with pancreatin alone (Figure 7C). We can hypothesise that the 414 
lesser digestion of zein matrix in SGF+SIF compared to SIF is due to an initial swelling and 415 
coalescence of the matrix in SGF, which partially impeded the following digestive action of 416 
the pancreatin in SIF.  417 
 418 
Overall, these findings indicate that zein extrudates were much more affected by the 419 
enzymatic digestion by the intestinal proteases than by the gastric pepsin. In agreement with 420 
our study, several other authors, although testing different dosage forms, have shown that 421 
zein is more sensitive to pancreatin than pepsin (Alqahtani et al., 2017; Fu et al., 2002; Hu et 422 
al., 2016; Hurtado-López and Murdan, 2006; Kanig and Goodman, 1962). Despite these 423 
studies, there still is a question mark on whether zein-based dosage forms are affected by the 424 
digestive enzymes or not. It has been suggested that a univocal answer cannot be given, as 425 
this depends on the type of dosage form and manufacturing process and it should be 426 
evaluated on a case by case (Berardi et al., 2018). Our extrudates were sensitive to digestion, 427 
yet the digestion only sped up the drug release without causing a sudden and unwanted drug 428 
release burst. In other words, the enzymes partially digested zein, causing a modulation of the 429 
drug release, but did not abolish the ability of zein matrix to control the drug release.  430 




4. Conclusions 435 
 436 
In this study, diclofenac sodium loaded zein based hot- melt extrudates were successfully 437 
produced. The drug was present in the non-crystalline state in zein extrudates at all drug 438 
loadings investigated. Drug loading as well as media parameters including ionic strength and 439 
presence of digestive enzymes influence the drug release rate were investigated. The results 440 
indicate that the extent of the controlled release is drug loading dependent. A nearly zero-441 
order release with no burst release was obtained at the lowest drug loading (12.5% w/w). 442 
Drug release rate can be further reduced by increasing ionic strength of medium, highlighting 443 
the potential influence of ionic strength in the gastro-intestinal tract on drug release from 444 
zein-based formulations. The presence of the digestive enzyme, namely pancreatin in 445 
simulated intestinal fluid significantly increased the drug release from zein extrudates by 446 
creating more pores through which the drug can diffuse. These results confirm the possibility 447 
of using zein as excipient in hot-melt extrusion for producing controlled release dosage 448 
forms.  449 
 450 
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